Efficacy of peg‐interferon‐α‐2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea

Sinn, Dong Hyun; Shin, Su Rin; Kil, Jae Sook; Kim, Jeong; Gwak, Geum‐Youn; Choi, Moon Seok; Lee, Joon Hyeok; Koh, Kwang Cheol; Yoo, Byung Chul; Paik, Seung Woon

doi:10.1111/j.1440-1746.2010.06478.x

Cited by 17 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been suggested that Asian CHC patients are more likely to have SVR than Caucasians 26. In accordance with these findings, Korean CHC patients seem to have better treatment outcomes, with SVR rates of 46% to 70% in genotype 1 infection and 76% to 94% in genotype 2/3 infection 10-13,27-30. Treatment outcome from Korean population is summarized in Table 4 (data from only published article was included).…”

Section: Discussionmentioning

confidence: 60%

“…These studies reported overall SVR rates of 63% to 81%, a range that seems to be somewhat higher than in Western countries 10-13. However, because there are a smaller proportion of CHC patients compared to chronic hepatitis B patients in Korea, it is difficult to perform a well-designed study to survey treatment efficacy for CHC in a single institution.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study

Park

Lee

et al. 2012

Gut Liver

View full text Add to dashboard Cite

Background/AimsWe aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for chronic hepatitis C (CHC) patients under real life setting in Korea.MethodsWe retrospectively analyzed the medical records of 758 CHC patients treated with peginterferon plus ribavirin between 2000 and 2008 from 14 university hospitals in the Gyeonggi-Incheon area in Korea.ResultsHepatitis C virus (HCV) genotype 1 was detected in 61.2% of patients, while genotype 2 was detected in 35.5%. Baseline HCV RNA level was ≥6×105 IU/mL in 51.6% of patients. The sustained virological response (SVR) rate was 59.6% regardless of genotype; 53.6% in genotype 1 and 71.4% in genotype 2/3. On multivariate analysis, male gender (p=0.011), early virological response (p<0.001), genotype 2/3 (p<0.001), HCV RNA <6×105 IU/mL (p=0.005) and adherence to the drug >80% of the planned dose (p<0.001) were associated with SVR. The rate of premature discontinuation was 35.7%. The main reason for withdrawal was intolerance to the drug due to common adverse events or cytopenia (48.2%).ConclusionsOur data suggest that the efficacy of peginterferon and ribavirin therapy in Koreans is better in Koreans than in Caucasians for the treatment of CHC, corroborating previous studies that have shown the superior therapeutic efficacy of this regimen in Asians.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Introductionmentioning

confidence: 99%

Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study

Park

Lee

et al. 2012

Gut Liver

View full text Add to dashboard Cite

show abstract

“…SVR rates in South Korea were reportedly higher; 53.6-69.5%228,245,266,267,268 and 62.7% in pooled analysis of 10 studies 269. This is related to the higher frequency of favorable IL28B genotypes in Koreans than in Whites or Blacks 81,244,252,254,270,271…”

Section: Treatment Of Genotypes 1 and 4 Chronic Hepatitis Cmentioning

confidence: 96%

“…However, treatment of elderly hepatitis C patients can decrease the incidence rate of HCC and increase the survival rate 226,227. A recent study reported that the SVR rate in patients >60 years of age is similar to that of patients in 50-59 years of age 228,229. Little data are available concerning treatment in those >70 years of age.…”

Section: Indications For Treatmentmentioning

confidence: 99%

KASL clinical practice guidelines: Management of Hepatitis C

2014

Clin Mol Hepatol

View full text Add to dashboard Cite

“…However, it is not known whether the rate of response in persons older than 65 years is the same as or worse than that for persons 40–65 years of age, because these studies excluded patients > 65 years old. A few reports concerning PEG-IFN-α-based combination treatment in elderly CHC patients have been published, and these found slightly different treatment outcomes [10][11][12][13]. …”

Section: Introductionmentioning

confidence: 99%

Treatment Response and Tolerability of Pegylated Interferon-α Plus Ribavirin Combination Therapy in elderly Patients (≥ 65 years) With Chronic Hepatitis C in Korea

Kim¹,

Kim²,

Jeon³

et al. 2012

Hepat Mon

View full text Add to dashboard Cite

BackgroundThe prevalence of hepatitis C virus (HCV) infections in elderly patients has been increasing in a number of countries. A few reports concerning pegylated interferon-α (PEG-IFN-α)-based combination treatment in elderly chronic hepatitis C (CHC) patients have been published, with slightly different treatment outcomes.ObjectivesWe investigated the treatment response and safety of PEG-IFN-α plus ribavirin combination therapy in elderly patients with CHC.Patients and MethodsAmong a total of 181 treatment-naïve CHC patients (60 patients with genotype 1, 121 patients with genotype 2 or 3), 38 were aged ≥ 65 years (defined as the elderly group) and 143 were aged < 65 years (defined as the non-elderly group).ResultsThe overall sustained virologic response (SVR) was lower in the elderly group than in the non-elderly group, but it was not significantly different (65.8 % vs. 76.2 %, P = 0.15). In a subgroup analysis, among patients with genotype 1, the elderly group had a significantly lower SVR rate than the non-elderly group (30.8 % vs. 66.0 %, P = 0.03). However, the SVR rate in patients with HCV genotype 2 or 3 was comparable between the two groups (84.0 % vs. 81.3 %, P = 0.85). HCV genotype was significantly associated with SVR in the elderly patients (genotype 1 vs. 2 or 3, odds ratio: 0.18, 95% confidence interval: 0.000-0.869, P = 0.03). The incidence of premature discontinuation of treatment (21.1 % vs. 9.1 %, P = 0.05) and dose modification (52.6 % vs. 31.5 %; P = 0.02) due mainly to adverse events or laboratory abnormalities, were higher in the elderly group than in the non-elderly group.ConclusionsPEG-IFN-α plus ribavirin combination therapy might be considered for elderly CHC patients, especially for genotype 2 or 3, with vigilant monitoring of adverse events.

show abstract

Efficacy of peg‐interferon‐α‐2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea

Abstract: Although physicians must pay more attention to adverse events in the older patients, combination therapy can be considered for older patients, especially for patients with a low APRI.

Cited by 17 publications

References 25 publications

Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study

Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study

KASL clinical practice guidelines: Management of Hepatitis C

Treatment Response and Tolerability of Pegylated Interferon-α Plus Ribavirin Combination Therapy in elderly Patients (≥ 65 years) With Chronic Hepatitis C in Korea

Contact Info

Product

Resources

About